ESPR News and Press, Esperion Therapeutics Inc.

– Targeted Campaign Reaches Patients at Risk for Heart Attack or Heart Procedures Because of High LDL Cholesterol (LDL-C) – – Animated Characters Are a Visual Representation of An Unseen Risk “Lurking” In Patients’ Artery Walls &...

2024-06-29 14:31:00 ET The S&P500 ( SP500 ) closed in the red on Friday, after an eventful week that saw companies including Micron Technology ( NASDAQ: MU ) and Nike ( NYSE: NKE ) posting quarterly results. The market also focused on inflation data and the first U.S...

– OMERS Life Sciences to Purchase Esperion’s European Royalty on Bempedoic Acid Products for $304.7 Million with European Royalties Reverting to Esperion Once OMERS Receives 1.7 Times its Investment – – Esperion Retains Rights to Receive all Poten...

2024-06-20 16:10:36 ET More on Esperion Therapeutics Buy Esperion Therapeutics Despite An Abiding Skepticism Weighing On The Stock Esperion's late stage trial of high cholesterol treatment met main goal Esperion Therapeutics beats top-line and bottom-line estimates; ...

2024-06-13 14:31:05 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Fundamentally, biotech stocks to buy operate on a clear and unavoidable narrative: wealth means nothing without health. You hear various stories about extremely wealthy tycoons throwing all...

2024-06-11 10:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investing in penny stocks can be a thrilling way to explore the potential for substantial gains. Despite their inherent risks, these stocks often appeal to adventurous investors looking to ...

ANN ARBOR, Mich., May 23, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following webcasted investor events during the month of May, which can be found on our investor relations website . Jefferies Global Healthcare Confer...

– NILEMDO (bempedoic acid), a First-In-Class, Oral Treatment and NUSTENDI (bempedoic Acid / Ezetimibe Fixed-Dose Combination) Receive Label Update Approval from The European Commission as Treatments to Reduce Cardiovascular Risk by Lowering Low-Density Lipoprotein Cholesterol (LDL-C) Level...

2024-05-20 08:33:13 ET More on Esperion Therapeutics Buy Esperion Therapeutics Despite An Abiding Skepticism Weighing On The Stock Esperion Therapeutics, Inc. (ESPR) Q1 2024 Earnings Call Transcript Esperion Therapeutics, Inc. 2024 Q1 - Results - Earnings Call Presen...

ANN ARBOR, Mich., May 20, 2024 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) and Otsuka Pharmaceutical Co., Ltd (Otsuka) announced today that the primary endpoint was achieved in the Phase 3 trial in Japan for bempedoic acid as a potential treatment for patients with hypercholesterolemia. The trial...